With a previous study demonstrating that CSF Aβ42, t-tau and p-tau levels are associated with the risk of progression to Alzheimer’s disease dementia in MCI patients,35 our findings suggest that measuring CSF 14-3-3β levels in MCI patients might also be a useful tool for identifying those at the highest risk of developing Alzheimer’s disease dementia. This evidence concerns the gene MAPT and Alzheimer disease.